Compare Nasdaq Inc (NDAQ) vs Natera Inc. Common Stock (NTRA) Price & Performance

Nasdaq (NDAQ) trades at $93.48, down 0.86% on the day, with strong technical momentum showing a bullish moving average signal despite overbought RSI conditions. The company demonstrates robust fundamentals with 2025 revenue of $8.26B and net income of $1.79B, representing a 21.64% profit margin. Recent earnings beats and the launch of AI-powered Calypso platform highlight operational strength. Analyst consensus remains strongly bullish with a $110.43 price target, representing 18% upside potential from current levels.

NDAQ presents a compelling investment case with consistent earnings outperformance, strong profitability metrics, and strategic AI integration driving growth. However, elevated valuation multiples (P/E 27.25) and potential market volatility from exchange operations pose risks. The stock's technical positioning near resistance at $95 requires monitoring, but institutional support and positive analyst sentiment suggest continued upside potential for long-term investors.

NTRA trades at $395.66, down 0.53% today but remains near recent highs. The stock shows mixed technical signals with neutral momentum indicators. Fundamentally, the company demonstrates strong revenue growth ($2.31B in 2025, projected $2.7B in 2026) but continues to operate at a net loss (-$208M in 2025). Recent positive developments include FDA Breakthrough Device designation for its multi-cancer detection assay and regulatory approval in Japan for Signatera.

NTRA presents a growth story with significant analyst support (89% buy ratings) but carries execution risks. The stock trades at premium valuations (P/S 20.48) while still unprofitable. Key catalysts include clinical trial progress and international expansion, though investors face risks from ongoing losses and competitive pressures in precision medicine.